CKD and Heart Disease: Early Stages Link Revealed
- Cardiovascular complications continued to define outcomes for people living with chronic kidney disease (CKD), even when kidney impairment was mild, according to a large systematic review that underscored...
- This review highlights the significantly elevated cardiovascular risk associated with Chronic Kidney Disease (CKD), even when accounting for conventional risk factors like hypertension, diabetes, and dyslipidemia.
- * Increased Risk: Individuals with CKD have a 1.4- to 2-fold higher risk of cardiovascular events or death compared to those without CKD.
Cardiovascular complications continued to define outcomes for people living with chronic kidney disease (CKD), even when kidney impairment was mild, according to a large systematic review that underscored how early cardiovascular risk emerged and intensified as renal function declined.
CKD stages, people with CKD consistently faced higher rates of coronary heart disease, stroke, and cardiovascular death than individuals without kidney disease. CKD affects an estimated 10% of the global population and remains one of the strongest nontraditional risk factors for cardiovascular disease (CVD)2 even though clinicians widely recognize that advanced CKD confers cardiovascular risk, uncertainty persists about how early that risk begins and how much it is indeed driven by kidney-specific mechanisms1.
The authors noted that cardiovascular disease remains the leading cause of death among people with CKD and that patients with reduced kidney function were often excluded from cardiovascular trials, limiting the applicability of guideline-based interventions. the review sought to consolidate existing data to better define the scope of risk and identify gaps in management strategies.
The systematic review followed PRISMA guidelines and included 7 studies published through December 2024. Study designs comprised prospective cohorts,cross-sectional analyses,and population-based cohorts. in total, the studies included more than 107,000 participants spanning a wide range of kidney function, from early CKD to dialysis-dependent disease.
Participants varied by age, sex, and geographic region. Several studies included predominantly middle-aged or older adults,reflecting the demographics of CKD populations seen in routine care. CKD staging was primarily defined by estimated glomerular filtration rate (eGFR
Summary of Cardiovascular Risk in Chronic Kidney Disease (CKD)
This review highlights the significantly elevated cardiovascular risk associated with Chronic Kidney Disease (CKD), even when accounting for conventional risk factors like hypertension, diabetes, and dyslipidemia. Here’s a breakdown of the key takeaways:
Key Findings:
* Increased Risk: Individuals with CKD have a 1.4- to 2-fold higher risk of cardiovascular events or death compared to those without CKD. This risk increases even in early stages of kidney disease – mild eGFR reductions are linked to a 50% higher risk of coronary heart disease and cardiovascular mortality. Some studies show a 4-fold higher 10-year cardiovascular risk.
* Beyond Traditional Factors: While traditional risk factors are common in CKD patients,nontraditional CKD-specific mechanisms (chronic inflammation,oxidative stress,uremic toxins,mineral metabolism disturbances,and anemia) significantly amplify cardiovascular risk.
* Coronary Microvascular Dysfunction: Impaired coronary flow reserve in CKD patients is a strong predictor of cardiac death, doubling the risk.
* Treatment Challenges: Standard cardiovascular interventions (antihypertensives, statins, glucose-lowering therapies) are often less effective in CKD due to disease-specific factors and competing risks.
* Promising Therapies: Newer therapies like SGLT2 inhibitors and GLP-1 receptor agonists show potential, but more long-term CKD-specific data is needed.
Implications for Clinical Practice:
* Early Identification: The review stresses the importance of identifying cardiovascular risk early in CKD patients.
* Individualized Management: A multimodal, individualized approach to management is crucial.
* Need for Research: There’s a call for CKD-inclusive cardiovascular trials, improved risk stratification tools, and interventions targeting both traditional and kidney-specific mechanisms.
Limitations of the Review:
* Observational Studies: Most studies were observational,limiting the ability to establish cause-and-effect relationships.
* Heterogeneity: Variations in CKD definitions, outcomes measured, and study durations made comparisons difficult.
* Data Gaps: Some studies lacked detailed stratification by CKD stage or fully adjusted risk estimates.
* Language Bias: Exclusion of non-English publications could introduce bias.
the review reinforces that cardiovascular risk is a major concern in CKD, beginning early in the disease process and requiring a proactive, thorough management strategy.